All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
Biomarkers for risk of chronic GvHD by age group
Results from a prospective multicenter study of allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients (children ≤10 years, n = 129; children/adults >10 years, n = 189) examining Day (D) 100 plasma biomarkers for chronic graft-versus-host disease (cGvHD) risk were recently published in Blood Advances by Ferreira et al.
Key data: Interleukin 1 receptor-like 1 (IL1RL1) and Dickkopf-WNT signaling pathway inhibitor-3 (DKK3) were associated with cGvHD in both age groups: IL1RL1, hazard ratio [HR], 2.35; p = 0.03 in ≤10 years; HR, 2.09; p = 0.01 in >10 years; and DKK3, HR, 2.39; p = 0.04 in ≤10 years; HR, 2.10; p = 0.01 in >10 years. C-X-C motif chemokine ligand 9 (CXCL9), regenerating-islet-derived-3-alpha (REG3α), and matrix metallopeptidase-3 (MMP3) were associated with cGvHD only in patients >10 years.
Key learning: D100 biomarkers measured post-allo-HSCT predict susceptibility and/or are prognostic for cGvHD and treatment-related mortality (TRM) in children aged ≤10 years and children/adults >10 years, allowing for additional risk stratification.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
When would you be most likely to consider prescribing belumosudil third-line and beyond?
